Alpine Immune Sciences Inc (ALPN) Receives Consensus Recommendation of “Buy” from Analysts

Alpine Immune Sciences Inc (NASDAQ:ALPN) has been given an average recommendation of “Buy” by the seven analysts that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $12.80.

Several brokerages recently issued reports on ALPN. Zacks Investment Research upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday. ValuEngine upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, November 21st. Oppenheimer set a $13.00 target price on shares of Alpine Immune Sciences and gave the company a “buy” rating in a research note on Monday, November 12th. Piper Jaffray Companies initiated coverage on shares of Alpine Immune Sciences in a research report on Thursday, September 27th. They set an “overweight” rating and a $12.00 price objective for the company. Finally, Raymond James initiated coverage on shares of Alpine Immune Sciences in a research report on Monday, August 13th. They set a “buy” rating and a $13.00 price objective for the company.

Hedge funds have recently modified their holdings of the business. DRW Securities LLC lifted its position in Alpine Immune Sciences by 138.7% during the second quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 14,143 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Alpine Immune Sciences by 122.2% in the second quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 18,052 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Alpine Immune Sciences by 20.9% in the second quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock valued at $927,000 after buying an additional 21,124 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Alpine Immune Sciences by 5.2% in the third quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock valued at $1,442,000 after buying an additional 11,200 shares in the last quarter. Hedge funds and other institutional investors own 56.82% of the company’s stock.

NASDAQ:ALPN traded down $0.02 during mid-day trading on Friday, hitting $4.80. The stock had a trading volume of 4,571 shares, compared to its average volume of 17,427. Alpine Immune Sciences has a twelve month low of $4.51 and a twelve month high of $11.75. The company has a market capitalization of $67.01 million, a P/E ratio of -4.03 and a beta of 0.94. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.20 and a current ratio of 9.20.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.31). Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 43.25%. As a group, equities analysts forecast that Alpine Immune Sciences will post -2.62 earnings per share for the current year.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Featured Story: Why is the Consumer Price Index (CPI) important?

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit